Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice

LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To characterize their effect on atherogenesis, APOE*3Leiden....

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Susanne, Rubil, Sandra, Endres, Matthias, Princen, Hans M. G., Boeckel, Jes-Niels, Winter, Karsten, Werner, Christian, Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668462/
https://www.ncbi.nlm.nih.gov/pubmed/31366894
http://dx.doi.org/10.1038/s41598-019-47242-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668462/
https://www.ncbi.nlm.nih.gov/pubmed/31366894
http://dx.doi.org/10.1038/s41598-019-47242-0

Ejemplares similares